For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Takeda Licenses Cervical Cancer Vaccine from JHSF
October 25, 2010
- Free Coupons for Cervical, Breast Cancer Exam Used by About 20% of Eligible Women
October 25, 2010
- Gilead's HBV Drug Licensed to GSK in Japan
October 25, 2010
- BIBW 2992 Extends PFS in NSCLC Patients: BI
October 25, 2010
- Risk Classification for 7 APIs Reviewed
October 25, 2010
- CMIC, Fujirebio to Collaborate to Market RENAPRO L-FABP Test
October 25, 2010
- US, EU Submissions for BSI-201 for mTNBC in 2011
October 25, 2010
- Chugai's Alliance with Roche Enters 2nd Phase
October 25, 2010
- Takepron Ranked No. 1 in HP Market: RepTrack Survey
October 25, 2010
- Kyowa Kirin to Report PII Results of KW-0761 at ASH
October 25, 2010
- Champix Demand Exceeds Supply Due To Tobacco Tax Increase
October 25, 2010
- Interim Report Presented on Sprycel PMS
October 25, 2010
- Sepracor Renamed Sunovion
October 25, 2010
- 1st-Line Japanese Cohort Analysis Data to Be Presented at ASH
October 25, 2010
- Korosho Requires Novo to Issue Blue Letter on Victoza
October 25, 2010
- Tasigna Effective in 1st-Line in Japanese CML Patients
October 25, 2010
- Korosho to Clarify Criteria for Requiring Safety Information
October 25, 2010
- Daiichi Sankyo, ArQule to Expand Research Collaboration in Oncology
October 25, 2010
- Korosho Proposes Safety Measures for Bisphosphonates
October 25, 2010
- BSI-201 Enters PI in Japan: sanofi-aventis
October 25, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…